Skip to main content

Table 3 societal costs associated with ranibizumab therapy for neovascular age-related macular degeneration

From: The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Parameter

Cost

Direct ophthalmic medical costs

 

 Ranibizumab therapy (81.3% bilateral)

$79,056

Direct non-ophthalmic medical costs

 Injury reduction

(−$664)

 Depression reduction

(−$2543)

 SNF cost decrease

(−$4100)

 Unexplained medical cost decrease

(−$28,598)

 Nursing home

(−$19,069)

 Total offsetting costs

(−$54,974)

 Total direct medical costs

$24,082

Direct non-medical costs

 Paid caregiver salariesa

(−$82,419)

 Salary gain for freed-up caregivers now able to take up gainful employment

(−$215,123)

 Total direct non-medical costs

(−$297,542)

Indirect medical costs

 Mean patient wage gain

(−$9057)

 Total societal costs

(−$282,517)

  1. All costs in 2015 U.S. real dollars, SNF skilled nursing facility
  2. aAs per Schmier et al. [22], 27.7% of caregiver costs are paid